Logo image of CMAX

CAREMAX INC (CMAX) Stock Fundamental Analysis

USA - NASDAQ:CMAX - US14171W2026 - Common Stock

0.4215 USD
-0.15 (-26.22%)
Last: 11/27/2024, 9:32:53 PM
0.3089 USD
-0.11 (-26.71%)
After Hours: 11/27/2024, 9:32:53 PM
Fundamental Rating

1

CMAX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 100 industry peers in the Health Care Providers & Services industry. CMAX may be in some trouble as it scores bad on both profitability and health. CMAX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CMAX has reported negative net income.
CMAX had a negative operating cash flow in the past year.
In the past 5 years CMAX always reported negative net income.
CMAX had a negative operating cash flow in each of the past 5 years.
CMAX Yearly Net Income VS EBIT VS OCF VS FCFCMAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -200M -400M -600M

1.2 Ratios

Looking at the Return On Assets, with a value of -172.42%, CMAX is doing worse than 95.45% of the companies in the same industry.
Industry RankSector Rank
ROA -172.42%
ROE N/A
ROIC N/A
ROA(3y)-37.96%
ROA(5y)N/A
ROE(3y)-373.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CMAX Yearly ROA, ROE, ROICCMAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CMAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMAX Yearly Profit, Operating, Gross MarginsCMAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -20 -40 -60 -80

More info and screens

0

2. Health

2.1 Basic Checks

CMAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CMAX has been increased compared to 1 year ago.
Compared to 1 year ago, CMAX has a worse debt to assets ratio.
CMAX Yearly Shares OutstandingCMAX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 1M 2M 3M
CMAX Yearly Total Debt VS Total AssetsCMAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

CMAX has an Altman-Z score of -3.22. This is a bad value and indicates that CMAX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CMAX (-3.22) is worse than 87.27% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.22
ROIC/WACCN/A
WACC8.41%
CMAX Yearly LT Debt VS Equity VS FCFCMAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 0.23 indicates that CMAX may have some problems paying its short term obligations.
CMAX has a worse Current ratio (0.23) than 93.64% of its industry peers.
A Quick Ratio of 0.23 indicates that CMAX may have some problems paying its short term obligations.
The Quick ratio of CMAX (0.23) is worse than 93.64% of its industry peers.
Industry RankSector Rank
Current Ratio 0.23
Quick Ratio 0.23
CMAX Yearly Current Assets VS Current LiabilitesCMAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

CMAX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1080.14%.
Looking at the last year, CMAX shows a quite strong growth in Revenue. The Revenue has grown by 9.06% in the last year.
EPS 1Y (TTM)-1080.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
Revenue 1Y (TTM)9.06%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-11.5%

3.2 Future

Based on estimates for the next years, CMAX will show a very strong growth in Earnings Per Share. The EPS will grow by 24.98% on average per year.
The Revenue is expected to grow by 16.33% on average over the next years. This is quite good.
EPS Next Y83.76%
EPS Next 2Y37.58%
EPS Next 3Y24.98%
EPS Next 5YN/A
Revenue Next Year5.97%
Revenue Next 2Y18.46%
Revenue Next 3Y16.94%
Revenue Next 5Y16.33%

3.3 Evolution

CMAX Yearly Revenue VS EstimatesCMAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B 2B 2.5B
CMAX Yearly EPS VS EstimatesCMAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMAX. In the last year negative earnings were reported.
Also next year CMAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMAX Price Earnings VS Forward Price EarningsCMAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMAX Per share dataCMAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 -100 200

4.3 Compensation for Growth

CMAX's earnings are expected to grow with 24.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.58%
EPS Next 3Y24.98%

More info and screens

0

5. Dividend

5.1 Amount

CMAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAREMAX INC

NASDAQ:CMAX (11/27/2024, 9:32:53 PM)

After market: 0.3089 -0.11 (-26.71%)

0.4215

-0.15 (-26.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-22 2024-11-22/amc
Earnings (Next)N/A N/A
Inst Owners40.82%
Inst Owner Change0%
Ins Owners22.94%
Ins Owner Change0%
Market Cap1.61M
Revenue(TTM)784.55M
Net Income(TTM)-782856000
Analysts45.71
Price Target43.25 (10160.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-28.17%
Min EPS beat(2)-29.48%
Max EPS beat(2)-26.86%
EPS beat(4)0
Avg EPS beat(4)-805.79%
Min EPS beat(4)-2482.51%
Max EPS beat(4)-26.86%
EPS beat(8)1
Avg EPS beat(8)-317.07%
EPS beat(12)3
Avg EPS beat(12)-265.4%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.7%
Min Revenue beat(2)-12.05%
Max Revenue beat(2)15.44%
Revenue beat(4)2
Avg Revenue beat(4)-4.22%
Min Revenue beat(4)-22%
Max Revenue beat(4)15.44%
Revenue beat(8)5
Avg Revenue beat(8)1.71%
Revenue beat(12)7
Avg Revenue beat(12)2.77%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)30.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-173.48
EYN/A
EPS(NY)-19.6
Fwd EYN/A
FCF(TTM)-16.26
FCFYN/A
OCF(TTM)-13.59
OCFYN/A
SpS205.92
BVpS-38.78
TBVpS-91.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -172.42%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.96%
ROA(5y)N/A
ROE(3y)-373.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.73
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.85%
Cap/Sales 1.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.23
Quick Ratio 0.23
Altman-Z -3.22
F-Score3
WACC8.41%
ROIC/WACCN/A
Cap/Depr(3y)46.3%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.82%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1080.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
EPS Next Y83.76%
EPS Next 2Y37.58%
EPS Next 3Y24.98%
EPS Next 5YN/A
Revenue 1Y (TTM)9.06%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-11.5%
Revenue Next Year5.97%
Revenue Next 2Y18.46%
Revenue Next 3Y16.94%
Revenue Next 5Y16.33%
EBIT growth 1Y-369.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.29%
EBIT Next 3Y30.61%
EBIT Next 5Y17.36%
FCF growth 1Y-9.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.24%
OCF growth 3YN/A
OCF growth 5YN/A

CAREMAX INC / CMAX FAQ

What is the ChartMill fundamental rating of CAREMAX INC (CMAX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CMAX.


What is the valuation status of CAREMAX INC (CMAX) stock?

ChartMill assigns a valuation rating of 1 / 10 to CAREMAX INC (CMAX). This can be considered as Overvalued.


What is the profitability of CMAX stock?

CAREMAX INC (CMAX) has a profitability rating of 0 / 10.


Can you provide the financial health for CMAX stock?

The financial health rating of CAREMAX INC (CMAX) is 0 / 10.